<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="346">
  <stage>Registered</stage>
  <submitdate>31/08/2005</submitdate>
  <approvaldate>2/09/2005</approvaldate>
  <actrnumber>ACTRN12605000273684</actrnumber>
  <trial_identification>
    <studytitle>A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma.</studytitle>
    <scientifictitle>Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma.</scientifictitle>
    <utrn />
    <trialacronym>MOTE - Minor Ocular Trauma in</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Emergency department presentations of corneal abrasion, corneal foreign bodies and UV keratitis.</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Dispensing 1.5 mL of eye drops, 0.4% amethocaine, for out-patient management of ocular pain in the first 48hr following the initial emergency department presentation with corneal abrasion, corneal foreign body or UV keratitis.</interventions>
    <comparator>0.9% saline</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Is there complete corneal re-epithelialisation (as defined by an absence of fluorescein uptake) at a follow-up visit 36-48hr following discharge from the initial assessment?  (yes/no)</outcome>
      <timepoint>36 - 48 hours following discharge from the intial assessment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of analgesia </outcome>
      <timepoint>Defined by marking a visual analogue scale every 3hr between initial and follow-up assessments.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Satisfaction with managment</outcome>
      <timepoint>Verbal numeric scale at 2wk following discharge.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>(a) Superficial corneal abrasion with clear history of trauma; (b) superficial corneal abrasion with foreign body; or (c) ultraviolet keratitis with clear history of welding flash exposure.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>(a) 36hr or more since event causing the corneal injury; (b) aged under 18yr; (c) history of any of - unacceptable adverse reaction to any local anaesthetic agent or to any ophthalmic preparation, visual impairment secondary to another eye pathology other than simple refractive error, contact lens use, previous participation in this trial, or current pregnancy/lactation; (d) signs of conjunctival infection; (e) functionally one-eyed; or (f) patient requiring referral for ophthalmological opinion.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Numbered containers, blinded contents of which are prepared by a research pharmacist otherwise not involved with the trial.  Treatment assignments kept secure at Pharmacy, unavailable to researchers involved with trial recruitment, execution, data collection and data entry until conclusion of trial data collection and entry.</concealment>
    <sequence>Batches of 16, with 8 amethocaine and 8 placebo assignments in each.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>Sample size determined by sequential analysis until data meets pre-defined endpoints supporting or refuting the hypothesis - hence no set sample size provided below.</designfeatures>
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>2/05/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>0</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Ken Barns</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Mater Foundation</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Joseph Ting</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>John Holmes</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A pilot study to investigate the safety of using local anaesthetic eye drops to control pain following minor corneal injuries.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Mater Health Services</ethicname>
      <ethicaddress>South Brisbane Q 4101</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Kenneth Barns</name>
      <address>c/- Department of Emergency Medicine
Mater Adults' Hospital
South Brisbane QLD 4101</address>
      <phone>+61 7 38408111</phone>
      <fax>+61 7 38401661</fax>
      <email>barns@uq.net.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kenneth Barns</name>
      <address>c/- Department of Emergency Medicine
Mater Adults' Hospital
South Brisbane QLD 4101</address>
      <phone>+61 7 38408111</phone>
      <fax>+61 7 38401661</fax>
      <email>barns@uq.net.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>